tradingkey.logo
tradingkey.logo
Search

Medpace Holdings Inc

MEDP
Add to Watchlist
417.290USD
-6.710-1.58%
Close 05/11, 16:00ETQuotes delayed by 15 min
11.92BMarket Cap
25.72P/E TTM

Medpace Holdings Inc

417.290
-6.710-1.58%

More Details of Medpace Holdings Inc Company

Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.

Medpace Holdings Inc Info

Ticker SymbolMEDP
Company nameMedpace Holdings Inc
IPO dateAug 11, 2016
CEOTroendle (August J)
Number of employees5900
Security typeOrdinary Share
Fiscal year-endAug 11
Address5375 Medpace Way
CityCINCINNATI
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code45227-1543
Phone15135799911
Websitehttps://investor.medpace.com/
Ticker SymbolMEDP
IPO dateAug 11, 2016
CEOTroendle (August J)

Company Executives of Medpace Holdings Inc

Name
Name/Position
Position
Shareholding
Change
Dr. August J. Troendle, M.D.
Dr. August J. Troendle, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
646.18K
--
Mr. Brian T. Carley
Mr. Brian T. Carley
Independent Director
Independent Director
32.83K
+0.03%
Mr. Stephen P. Ewald, J.D.
Mr. Stephen P. Ewald, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
20.34K
+17.20%
Mr. Jesse J. Geiger, CPA
Mr. Jesse J. Geiger, CPA
President
President
15.00K
--
Mr. Robert O. Kraft
Mr. Robert O. Kraft
Independent Director
Independent Director
955.00
+0.94%
Ms. Susan E. Burwig
Ms. Susan E. Burwig
Executive Vice President - Operations
Executive Vice President - Operations
--
--
Mr. Fred B. Davenport, Jr.
Mr. Fred B. Davenport, Jr.
Lead Independent Director
Lead Independent Director
--
--
Mr. Cornelius P. Mccarthy, III
Mr. Cornelius P. Mccarthy, III
Independent Director
Independent Director
--
--
Mr. Kevin M. Brady
Mr. Kevin M. Brady
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Femida H. Gwadry-Sridhar
Dr. Femida H. Gwadry-Sridhar
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. August J. Troendle, M.D.
Dr. August J. Troendle, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
646.18K
--
Mr. Brian T. Carley
Mr. Brian T. Carley
Independent Director
Independent Director
32.83K
+0.03%
Mr. Stephen P. Ewald, J.D.
Mr. Stephen P. Ewald, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
20.34K
+17.20%
Mr. Jesse J. Geiger, CPA
Mr. Jesse J. Geiger, CPA
President
President
15.00K
--
Mr. Robert O. Kraft
Mr. Robert O. Kraft
Independent Director
Independent Director
955.00
+0.94%
Ms. Susan E. Burwig
Ms. Susan E. Burwig
Executive Vice President - Operations
Executive Vice President - Operations
--
--

Revenue Breakdown

Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
By BusinessUSD
Name
Revenue
Proportion
Oncology
747.59M
29.55%
Metabolic
744.96M
29.44%
Other
408.55M
16.15%
Central Nervous System
254.84M
10.07%
Cardiology
239.37M
9.46%
AVAI
134.94M
5.33%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Oncology
747.59M
29.55%
Metabolic
744.96M
29.44%
Other
408.55M
16.15%
Central Nervous System
254.84M
10.07%
Cardiology
239.37M
9.46%
AVAI
134.94M
5.33%

Shareholding Stats

Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Medpace Investors, L.L.C.
16.57%
BlackRock Institutional Trust Company, N.A.
7.58%
AQR Capital Management, LLC
4.73%
Vanguard Portfolio Management, LLC
3.93%
Vanguard Capital Management, LLC
3.54%
Other
63.66%
Shareholders
Shareholders
Proportion
Medpace Investors, L.L.C.
16.57%
BlackRock Institutional Trust Company, N.A.
7.58%
AQR Capital Management, LLC
4.73%
Vanguard Portfolio Management, LLC
3.93%
Vanguard Capital Management, LLC
3.54%
Other
63.66%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.93%
Investment Advisor/Hedge Fund
26.57%
Corporation
16.57%
Hedge Fund
5.86%
Research Firm
3.18%
Individual Investor
2.85%
Pension Fund
1.93%
Family Office
1.65%
Family Office
1.65%

Institutional Shareholding

Updated: Sun, Apr 5
Updated: Sun, Apr 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
1402
24.53M
85.88%
-2.46M
2025Q4
1326
24.49M
86.95%
-4.74M
2025Q3
1221
26.75M
94.97%
-1.63M
2025Q2
1184
32.22M
114.46%
-1.64M
2025Q1
1189
32.19M
111.84%
-1.65M
2024Q4
1154
31.87M
104.30%
-1.77M
2024Q3
1089
31.75M
102.26%
-1.23M
2024Q2
1042
31.55M
102.01%
-1.83M
2024Q1
995
31.67M
102.27%
-1.17M
2023Q4
938
31.80M
103.67%
-407.87K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Medpace Investors, L.L.C.
4.73M
16.68%
--
--
Nov 28, 2025
BlackRock Institutional Trust Company, N.A.
2.16M
7.62%
+59.12K
+2.81%
Dec 31, 2025
AQR Capital Management, LLC
1.35M
4.76%
+324.29K
+31.63%
Dec 31, 2025
Wasatch Global Investors Inc
648.31K
2.28%
-277.66K
-29.99%
Dec 31, 2025
Geode Capital Management, L.L.C.
667.30K
2.35%
+24.63K
+3.83%
Dec 31, 2025
State Street Investment Management (US)
664.89K
2.34%
-8.25K
-1.23%
Dec 31, 2025
Troendle (August J)
646.18K
2.28%
-29.54K
-4.37%
Dec 03, 2025
D. E. Shaw & Co., L.P.
528.23K
1.86%
-71.91K
-11.98%
Dec 31, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Franklin Genomic Advancements ETF
5.91%
Invesco Dorsey Wright Healthcare Momentum ETF
5.53%
Argent Mid Cap ETF
5.35%
Aztlan Global Stock Selection DM SMID ETF
4.2%
Invesco S&P MidCap Quality ETF
4.17%
Invesco S&P MidCap 400 GARP ETF
3.39%
Janus Henderson Small/Mid Cap Growth Alpha ETF
3.14%
ERShares Entrepreneurs ETF
3.08%
Congress SMid Growth ETF
3%
Pacer US Large Cap Cash Cows Growth Leaders ETF
2.49%
View more
Franklin Genomic Advancements ETF
Proportion5.91%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion5.53%
Argent Mid Cap ETF
Proportion5.35%
Aztlan Global Stock Selection DM SMID ETF
Proportion4.2%
Invesco S&P MidCap Quality ETF
Proportion4.17%
Invesco S&P MidCap 400 GARP ETF
Proportion3.39%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proportion3.14%
ERShares Entrepreneurs ETF
Proportion3.08%
Congress SMid Growth ETF
Proportion3%
Pacer US Large Cap Cash Cows Growth Leaders ETF
Proportion2.49%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI